Production of glucagon like peptide 2 and analogs

a technology of glucagon and peptide, which is applied in the field of protein production, can solve the problems of limited product yield and quality in the prior art production system, and achieve the effect of high yield

Inactive Publication Date: 2011-04-21
NPS PHARM INC
View PDF45 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]In accordance with the present invention, there is provided a process by which GLP-2 and analogs thereof are produced not only in relatively high yield, but also as structurally authentic products, comprising only the natural form of the naturally occurring amino acids in the sequence constituting the GLP-2 peptide. Preferably, the N- and C-terminal residues are “terminally authentic”. In particular, the present process yields the desired GLP-2 as a peptide having N- and C-terminal residues that are without residual amino acids and other chemical moieties that often result from recombinant methods of protein production, particularly those which rely on production of the protein as a fused precursor from which the target protein must be released.

Problems solved by technology

However, prior art production systems have limitations in terms of product yield and quality, and it would be desirable to provide a system that yields quality GLP-2 peptide in a cost-effective manner.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Production of glucagon like peptide 2 and analogs
  • Production of glucagon like peptide 2 and analogs
  • Production of glucagon like peptide 2 and analogs

Examples

Experimental program
Comparison scheme
Effect test

example 1

Gene Construction

[0043]To construct multimers of [Gly2]hGLP-2 gene, a [Gly2]hGLP-2 gene, as shown below, was first amplified by PCR using a plasmid, pG3M, which carried a codon optimized [Gly2]hGLP-2 gene and was re-named as pEW3G.

[0044]As shown in FIG. 1, the forward PCR primer sequence (Primer KS1-5) contained NdeI and Bsal endonuclease recognition sites, and thrombin cleavage site, which are followed by 18 nucleotides encoding the first six amino acids of [Gly2]hGLP-2.

[0045]The reverse PCR primer (Primer KS2-3) contained BamHI and Bsal endonuclease recognition sites, acid cleavage site, and an 18 nucleotide sequence, which encode the last six amino acid residues of [Gly2]hGLP-2.

[0046]For PCR reaction, the lower PCR reaction mixture was first prepared in a PCR tube. The lower mixture contained 41 μL of water, 5 of 10×TsgPlus buffer, 2 μL of deoxynucleotide mixture (2.5 mM each), 1 μL of primer KS 1-5 (100 pM), and 1 μL of primer KS2-3 (100 pM). To the lower mixture, a piece of Amp...

example 2

Vector Construction

[0057]To construct multimers of [Gly2]hGLP-2 gene, pKS35 was digested with Bsal at 50° C. for 2.5 hour and separated on 1.5% agarose gel. The larger DNA band (the vector portion) was cut out of the gel and DNA was extracted from the gel piece using QIA quick gel extraction kit. The smaller DNA band (the insert, approximately 110 bp) was cut out of the gel and the DNA was extracted using QIA ExII. The large vector portion was further treated with calf intestine alkaline phosphatase (CIP) to minimize self-ligation of the vector and purified by QIAPCR purification kit.

[0058]The CIP-treated vector DNA and the smaller insert DNA were mixed and ligated using Quick T4 ligase. The ligation mixture was used to transform DH5α, as described above, and then the bacteria cells were plated 2×Yeast Extract (2×YE) agar plates containing kanamycin (30 μg / mL).

[0059]To examine the number of [Gly2]hGLP-2 gene units present on plasmid in each transformant, the inserts were directly am...

example 3

Transformation and Culturing

[0065]The [Gly2]hGLP-2 multimer constructs were cloned into a plasmid pET29a in such a way that they were expressed under the control of phage T7 promoter. E. coli RNA polymerase cannot recognize the T7 promoter. T7 RNA polymerase is required for the transcription from T7 promoter. E. coli strain, BLR(DE3), carries a phage T7 RNA polymerase gene on its chromosome. Moreover, recA gene in BLR(DE3) is inactivated so that the chance of losing [Gly2]hGLP-2 gene units in the multimer constructs by homologous recombination is minimal in this strain. Both DH5α. and BLR(DE3) strains are available commercially, as is the T7 system used herein.

[0066]The pET29a carrying a hexamer construct of [Gly2]hGLP-2 was designated as pKS58 and isolated from the transformant cells using Qiagen Plasmid Midi Prep kit. The frozen competent cells of BLR(DE3) (20 μL) were thawed, mixed with 1 μL of pKS58, kept on ice for 5 minutes, heat-shocked at 42° C. for 30 sec, and then kept on ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

GLP-2 peptides and analogs thereof are produced in high yield and with desired, authentic termini by isolation from a GLP-2 peptide multimer in which at least two units of GLP-2 peptide are coupled through a linker that presents an N-terminal acid cleavage site and a C-terminal enzyme cleavage site. In a specific embodiment, [Gly2]hGLP-2 is produced from a multimeric precursor comprising 2-30 units thereof.

Description

RELATED APPLICATIONS[0001]This application is a divisional of U.S. patent application Ser. No. 10 / 993,127, filed Nov. 22, 2004, which claimed priority to U.S. Provisional Application No. 60 / 523,667, filed Nov. 21, 2003, which applications are incorporated by reference.FIELD OF THE INVENTION[0002]This invention applies the art of molecular biology in the field of protein production. More particularly, the invention relates to the production of recombinant glucagon-like peptide 2, or GLP-2, and analogs thereof.BACKGROUND TO THE INVENTION[0003]GLP-2 is a 33 amino acid product of the proglucagon gene. Recent evidence indicates that GLP-2 promotes nutrient absorption via expansion of the mucosal epithelium by stimulation of crypt cell proliferation and inhibition of apoptosis in the small intestine. GLP-2 also reduces epithelial permeability, and decreases meal-stimulated gastric acid secretion and gastrointestinal mobility. Many of these effects have been attributed not only to the wild...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/00C07K14/00C12P21/06C07H21/04C07K14/605C12N1/21C12N15/74
CPCC07K2319/00C07K14/605
Inventor SASAKI, KENWILLIAMSON, VANESSA JANEDE ARAUJO, ALBERTOWALCZYK, EWA
Owner NPS PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap